236 related articles for article (PubMed ID: 37328530)
1. Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis.
Nguyen TT; Nhu NT; Tran VK; Viet-Nhi NK; Ho XD; Jhan MK; Chen YP; Lin CF
Sci Rep; 2023 Jun; 13(1):9775. PubMed ID: 37328530
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Nguyen TT; Thanh Nhu N; Tran VK; Van Cau N; Lin CF
J Immunother; 2023 Oct; 46(8):299-309. PubMed ID: 37216406
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis.
Nguyen TT; Nhu NT; Tran VK; Nguyen TTH; Lin CF
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046657
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
Yin S; Zheng X; Zhang W; Zhao H; Zhang R; Li W; Chen F
Ann Hematol; 2023 Oct; ():. PubMed ID: 37843620
[TBL] [Abstract][Full Text] [Related]
5. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
Bauer K; Rancea M; Roloff V; Elter T; Hallek M; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008079. PubMed ID: 23152253
[TBL] [Abstract][Full Text] [Related]
6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia.
Liu X; Hu B; Peng N; Chen L; Hu D; Zhang J; Wang L; Xie Z; Niu S; Lu Q; Lu J; Fang Y
Clin Exp Med; 2023 Dec; 23(8):4237-4248. PubMed ID: 37831432
[TBL] [Abstract][Full Text] [Related]
8. Is there a role for anti-CD20 antibodies in CLL?
Shah HR; Stephens DM
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):68-75. PubMed ID: 34889417
[TBL] [Abstract][Full Text] [Related]
9. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
Bennett R; Anderson MA; Seymour JF
J Hematol Oncol; 2023 Jul; 16(1):72. PubMed ID: 37422670
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab for patients with chronic lymphocytic leukaemia.
Skoetz N; Bauer K; Elter T; Monsef I; Roloff V; Hallek M; Engert A
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD008078. PubMed ID: 22336834
[TBL] [Abstract][Full Text] [Related]
12. Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials.
Rizzuto A; Pirrera A; Gigliotta E; Mancuso S; Vullo C; Camarda GM; Rotolo C; Roppolo A; Spoto C; Gentile M; Botta C; Siragusa S
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373078
[TBL] [Abstract][Full Text] [Related]
13. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
14. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
Fakhri B; Emechebe N; Manzoor BS; Jawaid D; Alhasani H; Edwards M; Tuncer HH
JCO Oncol Pract; 2024 Apr; ():OP2300630. PubMed ID: 38626366
[TBL] [Abstract][Full Text] [Related]
15. Frontline treatment in CLL: the case for time-limited treatment.
Lévy V; Delmer A; Cymbalista F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):59-67. PubMed ID: 34889444
[TBL] [Abstract][Full Text] [Related]
16. Update on the management of relapsed/refractory chronic lymphocytic leukemia.
Bennett R; Seymour JF
Blood Cancer J; 2024 Feb; 14(1):33. PubMed ID: 38378673
[TBL] [Abstract][Full Text] [Related]
17. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
[TBL] [Abstract][Full Text] [Related]
18. The impact of Bruton's tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia.
Yang S; Wei R; Shi H; Wang Y; Lai Y; Zhao X; Lu J; Schmitz N
Front Oncol; 2024; 14():1396913. PubMed ID: 38835372
[TBL] [Abstract][Full Text] [Related]
19. The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
Catania G; Tavarozzi R; Pini GM; Borra T; Gandolfo C; Zacchi G; Pietrasanta D; Monaco F; Zanni M; Lettieri M; Rivela P; Zallio F; Ladetto M
J Basic Clin Physiol Pharmacol; 2023 May; 34(3):401-404. PubMed ID: 37040263
[TBL] [Abstract][Full Text] [Related]
20. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]